Moleculin Biotech, Inc. (NASDAQ:MBRX) Stock Short Interest Rises 61.5%

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 287,608 shares, a growth of 61.5% from the August 31st total of 178,126 shares. Based on an average daily trading volume, of 652,899 shares, the short-interest ratio is presently 0.4 days. Approximately 1.8% of the shares of the company are short sold.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. HC Wainwright decreased their price objective on Moleculin Biotech to $3.00 and set a “buy” rating for the company in a report on Friday, August 28th. Wall Street Zen raised shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.00.

Moleculin Biotech Stock Down 4.1%

MBRX traded down $0.02 during trading on Wednesday, reaching $0.51. 667,570 shares of the company were exchanged, compared to its average volume of 653,760. The company’s 50-day moving average is $0.78 and its two-hundred day moving average is $1.87. The company has a market cap of $9.84 million, a price-to-earnings ratio of -0.07 and a beta of 1.92. Moleculin Biotech has a 12-month low of $0.16 and a 12-month high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.55) by $0.15. Equities analysts forecast that Moleculin Biotech will post -2.37 earnings per share for the current year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancers that are difficult to treat or have limited therapeutic options. The company’s research programs target cancer-cell survival mechanisms, drug resistance and tumor metabolism.

Moleculin’s lead product candidate is annamycin, a liposomal formulation of doxorubicin designed to retain anticancer activity while reducing the risk of cardiotoxicity associated with some conventional anthracyclines.